CCDC6-RET fusion is the second-most common RET fusion in NSCLC (~10-20%). Response to sel...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-RET-CCDC6-NSCLC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-NSCLC |
| Sources | SRC-CIVIC SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Actionability Facts
| Biomarker | BIO-RET |
|---|---|
| Variant | CCDC6-RET fusion |
| Disease | DIS-NSCLC |
| ESCAT tier | IA |
| Recommended combinations | selpercatinib monotherapy, pralsetinib monotherapy |
| Evidence summary | CCDC6-RET fusion is the second-most common RET fusion in NSCLC (~10-20%). Response to selective RET-TKIs (selpercatinib LIBRETTO-001, pralsetinib ARROW) is comparable to KIF5B-RET — fusion-partner identity does not currently modify treatment selection. |
Notes
ESCAT IA. OncoKB Level 1.
Used By
No reverse references found in the YAML corpus.